Core Viewpoint - BeiGene's stock experienced a slight decline of 0.73% on March 31, with a trading volume of 738 million yuan, indicating a low financing balance relative to its market value [1] Financing Summary - On March 31, BeiGene had a financing buy amount of 63.91 million yuan and a financing repayment of 50.01 million yuan, resulting in a net financing purchase of 13.91 million yuan [1] - The total financing and securities balance for BeiGene reached 855 million yuan, with the financing balance at 836 million yuan, accounting for 3.11% of the circulating market value, which is below the 30th percentile level over the past year [1] Securities Lending Summary - On March 31, BeiGene repaid 4,026 shares in securities lending and sold 2,838 shares, with the selling amount calculated at 662,900 yuan [1] - The remaining securities lending volume was 79,400 shares, with a balance of 18.56 million yuan, exceeding the 90th percentile level over the past year, indicating a high level [1] Company Overview - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is located in Changping District, Beijing, and focuses on the research, development, production, and commercialization of innovative drugs [1] - The company's main revenue sources are 99.10% from drug sales and 0.90% from collaboration arrangements [1] Shareholder Information - As of September 30, 2025, BeiGene had 36,200 shareholders, an increase of 55.33% from the previous period, while the average circulating shares per person decreased by 35.79% to 3,195 shares [2] - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, up 130.88% year-on-year [2] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [2]

Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative pharmaceuticals, particularly in the context of China's biopharmaceutical sector and its international expansion - **Market Growth**: The total value of BD (Business Development) transactions for innovative drugs is projected to reach $137.7 billion by 2025, a 1.6 times increase year-on-year, significantly surpassing the electric vehicle sector's $74 billion in the same timeframe [1][2][3] Core Insights and Arguments - **International Expansion**: The innovative drug sector is experiencing explosive growth in international markets, with Q1 2026 BD transactions already reaching $60 billion, accounting for 46% of the total for 2025 [1][2] - **Policy Support**: Biopharmaceuticals have been designated as a new pillar industry by the Chinese government, shifting focus from public welfare to GDP contribution, indicating a supportive policy environment for growth [2][3] - **Performance Expectations**: Companies like Heng Rui Medicine are expected to see over 30% growth in innovative drug revenue by 2026, with significant contributions from key products [1][3] - **Clinical Developments**: Major clinical data releases are anticipated from key conferences such as AACR and ASCO, which could catalyze market movements [1][5] Notable Companies and Their Prospects - **Heng Rui Medicine**: Expected to achieve over 30% growth in innovative drug revenue, with a strong pipeline of 53 products anticipated for approval between 2022 and 2028 [15] - **Kangfang Biopharma**: Key product AK112 is set to release critical clinical data in 2026, which could significantly impact its market position [11][13] - **Baiyi Shenzhou**: Projected profits of $700-800 million in 2026, indicating a rapid profit climb [1][8] - **Xinda Biopharma**: Anticipated to benefit from new product approvals and commercial launches, with a focus on expanding its product pipeline [6][8] Investment Opportunities - **Recommended Stocks**: Key investment targets include Kangfang Biopharma, Xinda Biopharma, Baiyi Shenzhou, and Kelong Biotechnology in the H-share market, and Xintai, Haishike, and Heng Rui Medicine in the A-share market [4][8] - **Undervalued Stocks**: Companies like Hot Scene Biopharma and Yifang Biopharma, which have seen significant price declines, are suggested for bottom-fishing opportunities [4][8] Emerging Trends - **Small RNA Technology**: The small RNA sector is entering a critical phase with breakthroughs in liver-targeted delivery technologies, and several companies are expected to announce significant clinical data in 2026 [18][22] - **Clinical Data Impact**: Recent clinical data from companies like Serapta and Wave Life Sciences highlight the potential and challenges within the small RNA space, influencing market sentiment and investment strategies [20][21] Conclusion - The innovative pharmaceutical sector in China is poised for significant growth driven by international expansion, supportive policies, and strong company performances. Key clinical events and emerging technologies present substantial investment opportunities, particularly in small RNA and innovative drug development.

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Core Viewpoint - The application for BGB-43395 tablets by BeiGene (Suzhou) Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration on March 28, 2026, with acceptance number CXHB2600089 [1][3]. Company Information - BeiGene (Suzhou) Biotechnology Co., Ltd. was established on April 9, 2015, and is a large-scale limited liability company wholly owned by Hong Kong and Macao investors [3][6]. - The legal representative of the company is Xiaobin Wu, and it operates in the field of medical research and experimental development [3][6]. - The company has a registered capital of approximately 4.973 billion RMB and a paid-in capital of approximately 3.444 billion RMB [3][6]. - The company is located in the Suzhou Industrial Park, Jiangsu Free Trade Zone, at Jin Hai Road No. 29 [3][6]. Application Details - The drug BGB-43395 is classified as a chemical drug and the application type is a supplementary application [2][4]. - The registration classification for the drug is categorized as type 1 [2][4].

Core Insights - The company achieved a total revenue of $5.343 billion in 2025, marking a year-on-year growth of 40.2%, with product revenue netting $5.282 billion, up 39.8% [1][3] - The company recorded a net profit of $287 million in 2025, a significant turnaround from a net loss of $645 million in the previous year, indicating a sustainable growth phase for its business model [1][3] Revenue Breakdown - The core product, Baiyueze, generated global sales of $3.928 billion, reflecting a 48.6% increase and maintaining its leading position among BTK inhibitors [1][3] - Baiyueze accounted for approximately 74% of total product revenue, while Baizean (Tislelizumab) contributed $737 million, up 18.8% [3] - Other products included Anjavi (Denosumab) with $306 million in revenue, up 36.4%, and Beilitai (Bonetuzumab) with $104 million, up 40.2% [3] Cash Flow and Profitability - Cash and cash equivalents reached $4.548 billion by the end of 2025, a 73.1% increase, with net cash flow from operating activities at $1.128 billion, a turnaround from a net outflow of $141 million in the previous year [1][3] - The gross profit for 2025 was $4.667 billion, with a gross margin of 87.3%, an improvement from 84.3% in 2024 [4] Cost Management - The increase in gross margin was attributed to a higher proportion of high-margin Baiyueze sales, ongoing optimization of manufacturing costs, and the gradual operationalization of the Hopewell production facility [4] - Research and development expenses rose to $2.146 billion, a 9.9% increase, while sales and administrative expenses reached $2.081 billion, up 13.7% [5][7] Financial Health - As of the end of 2025, total assets amounted to $8.189 billion, with shareholder equity at $4.361 billion and total liabilities at $3.827 billion [7] - The company secured a credit agreement with HSBC and other financial institutions for approximately $768 million to refinance short-term operational funding [7] Pipeline Progress - The company is advancing its pipeline with the approval of Sotoclis (a next-generation BCL2 inhibitor) for treating relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia, with FDA priority review status [8] - The HERIZON-GEA-01 study for Baihe'an (Zanidatamab) achieved positive endpoints, paving the way for a market application for HER2-positive gastric esophageal adenocarcinoma [8]

Group 1 - The company announced the appointment of Ernst & Young Huaming as the annual audit institution for its A-share financial statements and internal controls [1] - Ernst & Young will serve as the annual audit institution for the company's Hong Kong stock financial statements [1] - Ernst & Young LLP has been appointed as the annual audit institution for the company's U.S. stock financial statements and internal controls [1] - Ernst & Young AG will act as the statutory auditor for the company in Switzerland [1]

Core Insights - The company achieved a milestone in 2025 by recording a net profit of $287 million, successfully turning around from a net loss of $645 million in the previous year, marking its first annual profit since inception [1] - Total revenue for the year reached $5.343 billion, representing a year-on-year growth of 40.2%, with product revenue netting $5.282 billion, up 39.8% [1] Revenue Breakdown - The core product, Baiyueze, generated $3.928 billion in global sales, a 48.6% increase, maintaining its leading position among BTK inhibitors [3] - Bai Ze An (Tislelizumab) contributed $737 million, growing by 18.8% [3] - Other products included Anjiao Wei (Denosumab) at $306 million, up 36.4%, and Beili Tuo (Bonetuzumab) at $104 million, up 40.2% [3] - Other income reached $60.97 million, a significant increase of 98.6%, primarily from royalties related to the collaboration with Amgen [4] Profitability and Cash Flow - Gross profit for 2025 was $4.67 billion, with a gross margin of 87.3%, up from 84.3% in 2024, driven by improved product mix and manufacturing efficiencies [5] - The company reported a net cash flow from operating activities of $1.128 billion, a turnaround from a net outflow of $141 million in the previous year [1] Cost Structure and Efficiency - Research and development expenses totaled $2.146 billion, a 9.9% increase, while sales and administrative expenses were $2.081 billion, up 13.7% [6] - The combined expenses accounted for 78.6% of product revenue, down from 90.2% the previous year, indicating improved operational leverage [6] Financial Health - As of the end of 2025, total assets were $8.189 billion, with shareholder equity at $4.361 billion and total liabilities at $3.827 billion [8] - The company secured approximately $768 million in term loans from financial institutions for refinancing short-term operational funding [8] Pipeline Progress - The company is advancing its pipeline with the approval of Sotokura (a new generation BCL2 inhibitor) expected in January 2026 for treating relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia [9] - The HERIZON-GEA-01 study for Bai He An (Zanidatamab) achieved positive endpoints, paving the way for a market application in HER2-positive gastric adenocarcinoma [9] - The company is uniquely positioned with potential best-in-class candidates across three key targets in chronic lymphocytic leukemia [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 截至2025年12月31日止年度 全年業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2025年12月31日止年度（「報告期」）的綜合業績連同2024年相應期間的 比較數字，其乃根據美國公認會計原則（「美國公認會計原則」或「GAAP」）編製並 由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 | | | 截至12月31日止年度 | | | --- | --- | --- | --- | | | 附註 | 2025 | 2024 | | | | 千美元 | 千美元 | | 收入 | | | | | 產品收入，淨額 | 15 | 5,282,061 | 3,779,546 | | 其他收入 | 3 | 60,972 | ...

Core Viewpoint - BeiGene (06160.HK) reported a significant revenue increase for the fiscal year ending December 31, 2025, with total revenue rising by approximately $1.5 billion or about 40.2% to around $5.3 billion [1] Financial Performance - Total revenue for the fiscal year ending December 31, 2025, increased by approximately $1.5 billion or about 40.2% to around $5.3 billion compared to the fiscal year ending December 31, 2024 [1] - Product revenue also saw a rise of approximately $1.5 billion or about 39.8% to around $5.3 billion for the same period [1] - The net profit for the fiscal year ending December 31, 2025, was approximately $287 million, a significant turnaround from a net loss of approximately $645 million for the fiscal year ending December 31, 2024 [1] - Basic and diluted earnings per share for the fiscal year ending December 31, 2025, were $0.20 [1] Product Performance - The product "Tislelizumab" (百悦泽®) maintains its leading position in global revenue among BTK inhibitors [1] - "Zanubrutinib" (百泽安®) continues to receive new indication approvals and broader reimbursement coverage across multiple markets [1] - The commercialization of hematologic oncology products is gradually progressing, while the solid tumor product portfolio is consistently delivering encouraging data [1]

Core Viewpoint - BeiGene is projected to achieve a revenue of $5.343 billion in 2025, representing a year-on-year growth of 40.2%. The company is also expected to report a net profit of $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1]. Financial Performance - Revenue for 2025 is estimated at $5.343 billion, indicating a growth rate of 40.2% compared to the previous year [1]. - The net profit is forecasted to be $287 million, contrasting with a net loss of $645 million in the same quarter of the previous year [1].